Targeted therapies are few for patients with HER2-negative breast cancer. A phase III trial presented at the ASCO Annual Meeting1 described a way to identify potential therapeutic benefit from a PARP inhibitor: BRCA status.
The OlympiAD trial demonstrated that the PARP inhibitor olaparib yielded improved survival over chemotherapy for HER2-negative metastatic breast cancer (mBC) patients with a BRCA variant. This targeted therapy is more effective and less toxic than the current regimens available to hormone-receptor-positive, triple-negative breast cancer patients.
Larger studies that investigate the differential treatment effects of olaparib among subgroups defined according to hormone-receptor status or previous use of platinum-based therapy, would be helpful in selecting the most effective treatment option for patients with breast cancer.1
1Mark E. Robson, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). J Clin Oncol 35, 2017 (suppl; abstr LBA4). Presented at ASCO Annual Meeting; June 2017; Chicago, Illinois.